In a phase 2 study the use of lapatinib in patients with advanced HER2 + BC resulted in objective response rate (ORR) of 24%, the median time to response (TTR) was 7.9 months, and the median duration of response (DOR) was 28.4 weeks. Here, ERBB2 is linked to breast cancer.